Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17024594 | 1.00 | CA1 (0.48) | CA1CA2POLBCYP4A11NPC1 | |
| SCHEMBL15637982 | 0.86 | POLB (0.52) | POLBNPC1RAB9AADRB2ADRB1 | |
| SCHEMBL17031963 | 0.86 | POLB (0.49) | POLBRAB9AADRB2ADRB1MEN1 | |
| SCHEMBL16780591 | 0.84 | HIF1A (0.48) | CA1CA2POLBCYP4A11NPC1 | |
| SCHEMBL16780589 | 0.84 | HIF1A (0.48) | CA1CA2POLBCYP4A11NPC1 | |
| SCHEMBL5269060 | 0.81 | CASR (0.56) | POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31521347 | 0.80 | CDC25A (0.49) | CA1CA2POLBNPC1RAB9A | |
| SCHEMBL8700888 | 0.80 | ADRB2 (0.50) | CA1CA2POLBCYP4A11RAB9A | |
| SCHEMBL17024692 | 0.80 | LOXL2 (0.46) | CA1CA2POLBCYP4A11NPC1 | |
| SCHEMBL17024693 | 0.80 | LOXL2 (0.46) | CA1CA2POLBCYP4A11NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603889-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2903998-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20150238558-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238558-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | CA1 3113/4885CA2 2599/4885POLB 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.